1. |
Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010:findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013, 381(9882):1987-2015.
|
2. |
Liu L, Wang D, Wong KS, et al. Stroke and stroke care in China:huge burden, significant workload, and a national priority[J]. Stroke, 2011, 42(12):3651-3654.
|
3. |
Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry (CNSR)[J]. Stroke, 2011, 42(6):1658-1664.
|
4. |
Dietl M1, Pohle R, Weingärtner M, et al. Stroke etiology and long-term need of care in ischemic stroke patients[J]. Fortschr Neurol Psychiatr, 2009, 77(12):714-719.
|
5. |
Gao S, Wang YJ, Xu AD, et al. Chinese ischemic stroke subclassification[J]. Front Neurol, 2011, 15(2):1-6.
|
6. |
重组组织型纤溶酶原激活剂治疗缺血性卒中共识专家组. 临床应用rt-PA静脉溶栓治疗缺血性卒中专家共识[J]. 中华内科杂志, 2006, 45(7):613-614.
|
7. |
胡大一, 郭艺芳. 心房颤动抗凝治疗中国专家共识[J]. 心脑血管病防治, 2012, 12(3):173-177.
|
8. |
他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识[J]. 中国卒中杂志, 2013, 8(7):565-575.
|
9. |
Cornett O, Ocava LC, Singh M, et al. Antithrombotic and thrombolytic therapy for ischemic stroke[J]. Cardiol Clin, 2008, 26(2):251-65.
|
10. |
周泽纯, 田杏音. 心源性脑栓塞急性期的护理观察[J]. 广州医药, 2013, 44(5):71-72.
|
11. |
Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemicstroke before and after a quality improvement initiative[J]. JAMA, 2014, 311(16):1632-40.
|
12. |
罗颖, 徐程莹. 康复训练和出院后康复督导对脑梗塞康复的影响[J]. 中华全科医学, 2011, 9(10):1646-1647.
|